155 related articles for article (PubMed ID: 21524578)
1. Macrocyclic chelator assembled RGD multimers for tumor targeting.
Zhang X; Liu H; Miao Z; Kimura R; Fan F; Cheng Z
Bioorg Med Chem Lett; 2011 Jun; 21(11):3423-6. PubMed ID: 21524578
[TBL] [Abstract][Full Text] [Related]
2. Cyclization of RGD peptide sequences via the macrocyclic chelator DOTA for integrin imaging.
Hao G; Sun X; Do QN; Ocampo-García B; Vilchis-Juárez A; Ferro-Flores G; De León-Rodríguez LM
Dalton Trans; 2012 Dec; 41(46):14051-4. PubMed ID: 23085681
[TBL] [Abstract][Full Text] [Related]
3. A macrocyclic chelator with unprecedented Th⁴⁺ affinity.
Pham TA; Xu J; Raymond KN
J Am Chem Soc; 2014 Jun; 136(25):9106-15. PubMed ID: 24870296
[TBL] [Abstract][Full Text] [Related]
4. Propylene cross-bridged macrocyclic bifunctional chelator: a new design for facile bioconjugation and robust (64)Cu complex stability.
Pandya DN; Bhatt N; An GI; Ha YS; Soni N; Lee H; Lee YJ; Kim JY; Lee W; Ahn H; Yoo J
J Med Chem; 2014 Sep; 57(17):7234-43. PubMed ID: 25137619
[TBL] [Abstract][Full Text] [Related]
5. Influence of chelate conjugation on a newly identified tumor-targeting peptide.
Mier W; Zitzmann S; Krämer S; Reed J; Knapp EM; Altmann A; Eisenhut M; Haberkorn U
J Nucl Med; 2007 Sep; 48(9):1545-52. PubMed ID: 17704241
[TBL] [Abstract][Full Text] [Related]
6. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles.
Lee HY; Li Z; Chen K; Hsu AR; Xu C; Xie J; Sun S; Chen X
J Nucl Med; 2008 Aug; 49(8):1371-9. PubMed ID: 18632815
[TBL] [Abstract][Full Text] [Related]
7. DFT study of the interaction between DOTA chelator and competitive alkali metal ions.
Frimpong E; Skelton AA; Honarparvar B
J Mol Graph Model; 2017 Sep; 76():70-76. PubMed ID: 28711759
[TBL] [Abstract][Full Text] [Related]
8. The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.
Varasteh Z; Mitran B; Rosenström U; Velikyan I; Rosestedt M; Lindeberg G; Sörensen J; Larhed M; Tolmachev V; Orlova A
Nucl Med Biol; 2015 May; 42(5):446-454. PubMed ID: 25684649
[TBL] [Abstract][Full Text] [Related]
9. Influence of macrocyclic chelators on the targeting properties of (68)Ga-labeled synthetic affibody molecules: comparison with (111)In-labeled counterparts.
Strand J; Honarvar H; Perols A; Orlova A; Selvaraju RK; Karlström AE; Tolmachev V
PLoS One; 2013; 8(8):e70028. PubMed ID: 23936372
[TBL] [Abstract][Full Text] [Related]
10. Bifunctional ligands based on the DOTA-monoamide cage.
Barge A; Tei L; Upadhyaya D; Fedeli F; Beltrami L; Stefanìa R; Aime S; Cravotto G
Org Biomol Chem; 2008 Apr; 6(7):1176-84. PubMed ID: 18362955
[TBL] [Abstract][Full Text] [Related]
11. Chiral DOTA chelators as an improved platform for biomedical imaging and therapy applications.
Dai L; Jones CM; Chan WTK; Pham TA; Ling X; Gale EM; Rotile NJ; Tai WC; Anderson CJ; Caravan P; Law GL
Nat Commun; 2018 Feb; 9(1):857. PubMed ID: 29487362
[TBL] [Abstract][Full Text] [Related]
12. Isomerism in benzyl-DOTA derived bifunctional chelators: implications for molecular imaging.
Payne KM; Woods M
Bioconjug Chem; 2015 Feb; 26(2):338-44. PubMed ID: 25635382
[TBL] [Abstract][Full Text] [Related]
13. The synthesis and chelation chemistry of DOTA-peptide conjugates.
De León-Rodríguez LM; Kovacs Z
Bioconjug Chem; 2008 Feb; 19(2):391-402. PubMed ID: 18072717
[TBL] [Abstract][Full Text] [Related]
14. Characterization and evaluation of DOTA-conjugated Bombesin/RGD-antagonists for prostate cancer tumor imaging and therapy.
Stott Reynolds TJ; Schehr R; Liu D; Xu J; Miao Y; Hoffman TJ; Rold TL; Lewis MR; Smith CJ
Nucl Med Biol; 2015 Feb; 42(2):99-108. PubMed ID: 25459113
[TBL] [Abstract][Full Text] [Related]
15. A benzimidazole functionalised DO3A chelator showing pH switchable coordination modes with lanthanide ions.
Fisher CM; Fuller E; Burke BP; Mogilireddy V; Pope SJ; Sparke AE; Déchamps-Olivier I; Cadiou C; Chuburu F; Faulkner S; Archibald SJ
Dalton Trans; 2014 Jul; 43(25):9567-78. PubMed ID: 24828602
[TBL] [Abstract][Full Text] [Related]
16. Influence of DOTA chelator position on biodistribution and targeting properties of (111)In-labeled synthetic anti-HER2 affibody molecules.
Perols A; Honarvar H; Strand J; Selvaraju R; Orlova A; Karlström AE; Tolmachev V
Bioconjug Chem; 2012 Aug; 23(8):1661-70. PubMed ID: 22768790
[TBL] [Abstract][Full Text] [Related]
17. A simple time-resolved fluorescence assay for quantitative determination of DOTA chelator.
Szkop M; Brygoła K; Janczewska M; Ciach T
Anal Biochem; 2019 Nov; 584():113384. PubMed ID: 31356774
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of copper-64 labeled AmBaSar conjugated cyclic RGD peptide for improved microPET imaging of integrin alphavbeta3 expression.
Cai H; Li Z; Huang CW; Shahinian AH; Wang H; Park R; Conti PS
Bioconjug Chem; 2010 Aug; 21(8):1417-24. PubMed ID: 20666401
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of nanoglobular macrocyclic Mn(II) chelate conjugates as non-gadolinium(III) MRI contrast agents.
Tan M; Ye Z; Jeong EK; Wu X; Parker DL; Lu ZR
Bioconjug Chem; 2011 May; 22(5):931-7. PubMed ID: 21473650
[TBL] [Abstract][Full Text] [Related]
20. Influence of nuclides and chelators on imaging using affibody molecules: comparative evaluation of recombinant affibody molecules site-specifically labeled with ⁶⁸Ga and ¹¹¹In via maleimido derivatives of DOTA and NODAGA.
Altai M; Strand J; Rosik D; Selvaraju RK; Eriksson Karlström A; Orlova A; Tolmachev V
Bioconjug Chem; 2013 Jun; 24(6):1102-9. PubMed ID: 23705574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
